14 recruiting, 8 active not recruiting, 6 completed, 6 terminated. 44 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Watchful Waiting: new trials by email Literature Review of Watchful Waiting trials Research Report on Watchful Waiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) Active Surveillance With ctHPVDNA (NavDx®) - Squamous Cell Carcinoma, Human Papilloma Virus (HPV) | Phase 2 | Recruiting | Medical University of South Carolina | 36 | 2026-08-12 | 2026-09-14 |
| Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy - Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 120 | 2026-05-30 | 2026-10-15 |
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) Belzutifan, Active Surveillance - Active Surveillance, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 78 | 2025-11-17 | 2026-05-22 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC Adebrelimab and nab-paclitaxel and carboplatin, Radiation, standard oesophagectomy - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Zhigang Li | 164 | 2025-07-01 | 2025-05-15 |
| Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W Maximum TURBT, Chemotherapy + Immunotherapy Induction, Radiotherapy - Muscle-invasive Bladder Cancer | Phase 2 | Recruiting | American University of Beirut Medical Center | 80 | 2025-06-11 | 2026-10-29 |
| Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial Active Surveillance - Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | University of Vermont Medical Center | 45 | 2025-06-05 | 2026-05-26 |
| MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer Short course radiation, Active Surveillance - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Recruiting | University of Vermont Medical Center | 24 | 2025-06-04 | 2026-05-26 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Clinical Observation - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Suspended | Mayo Clinic | 236 | 2024-05-03 | 2026-08-20 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Atezolizumab, Biospecimen Collection, Carboplatin - Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 189 | 2022-06-28 | 2026-11-06 |
| Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7) - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | BioNTech SE | 1380 | 2021-08-25 | 2024-11-22 |
| White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Clinical Observation, Patient Observation, Questionnaire Administration - Prostate Adenocarcinoma, PSA Failure | Phase 2 | Suspended | City of Hope Medical Center | 133 | 2021-05-10 | 2026-11-04 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2021-03-17 | 2026-05-22 |
Showing 20 of 44. Sign in to see all of them.
Prostatic Neoplasms (8) · Colonic Neoplasms (4) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Melanoma (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Anorexia (1) · Body Weight Changes (1) · Brain Neoplasms (1) · COVID-19 (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4) · Mayo Clinic (4) · Alliance for Clinical Trials in Oncology (3) · City of Hope Medical Center (2) · NRG Oncology (2) · University of Vermont Medical Center (2) · 4D Molecular Therapeutics (1) · Academic and Community Cancer Research United (1) · American University of Beirut Medical Center (1) · Astellas Pharma Global Development, Inc. (1) · BioNTech SE (1) · Children's Cancer and Leukaemia Group (1) · Children's Oncology Group (1) · ECOG-ACRIN Cancer Research Group (1)
United States (36) · Canada (6) · China (3) · Puerto Rico (2) · Australia (1) · Germany (1) · Hong Kong (1) · India (1) · Ireland (1) · Lebanon (1) · Netherlands (1) · Singapore (1) · South Africa (1) · Taiwan (1) · Turkey (Türkiye) (1)
Alexander Shoushtari (1) · Anna C Ferrari (1) · Anna R. Brandon, PhD, MSCS (1) · Arkadiusz Dudek, MD (1) · Bhishamjit Chera, MD (1) · Bouthaina S Dabaja (1) · Brian T Hess (1) · Brittani K Seynnaeve (1) · Bruno De Bernardi, MD (1) · Chad Tang (1) · Clayton S Lau (1) · David B Zhen (1) · Donald L. Trump, MD (1) · Eric Jonasch, MD (1)
PMID 18408401, PMID 18408402, PMID 21569373, PMID 27789196, PMID 31678224, PMID 33394722, PMID 33627312, PMID 35708696, PMID 36378074, PMID 37527039, PMID 38635932, PMID 39097927, PMID 39390760, PMID 39928953, PMID 39938471, PMID 40742002, PMID 40851456, PMID 41609418, PMID 41757539, PMID 42117295, PMID 42567733, PMID 42949119
U10CA180820 (3), P30CA033572 (2), U10CA180821 (2), U10CA180868 (2), U10CA180888 (2), N01CM00071 (1), P30CA014599 (1), P30CA015083 (1), P30CA016056 (1), P30CA138292 (1), R01CA286127 (1), R01CA300454 (1), U10CA021115 (1), U10CA021661 (1), U10CA031946 (1)